A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations

• Type: Another Publication in an International Scientific Journal
• Date: 2022

Authors

Mahon, J (Author) Other; Beale, S (Author) Other; Holmes, H (Author) Other; Arber, M (Author) Other; Nikolayevskyy, V (Author) Other; Alagna, R (Author) Other; Manissero, D (Author) Other; Dowdy, D (Author) Other; Migliori, GB (Author) Other; Sotgiu, G (Author) Other; Duarte R (Author) ICBAS

Journal

Title: BMC Pulmonary Medicine

Vol. 22

ISSN: 1471-2466

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-00X-AEX

DOI: 10.1186/s12890-022-02149-x

Abstract (EN): Background The World Health Organisation (WHO) recommends that testing and treatment for latent tuberculosis infection (LTBI) should be undertaken in high-risk groups using either interferon gamma release assays (IGRAs) or a tuberculin skin test (TST). As IGRAs are more expensive than TST, an assessment of the cost-effectiveness of IGRAs can guide decision makers on the most appropriate choice of test for different high-risk populations. This current review aimed to provide the most up to date evidence on the cost-effectiveness evidence on LTBI testing in high-risk groups-specifically evidence reporting the costs per QALY of different testing strategies. Methods A comprehensive search of databases including MEDLINE, EMBASE and NHS-EED was undertaken from 2011 up to March 2021. Studies were screened and extracted by two independent reviewers. The study quality was assessed using the Bias in Economic Evaluation Checklist (ECOBIAS). A narrative synthesis of the included studies was undertaken. Results Thirty-two studies reported in thirty-three documents were included in this review. Quality of included studies was generally high, although there was a weakness across all studies referencing sources correctly and/or justifying choices of parameter values chosen or assumptions where parameter values were not available. Inclusions of IGRAs in testing strategies was consistently found across studies to be cost-effective but this result was sensitive to underlying LTBI prevalence rates. Conclusion While some concerns remain about uncertainty in parameter values used across included studies, the evidence base since 2010 has grown with modelling approaches addressing the weakness pointed out in previous reviews but still reaching the same conclusion that IGRAs are likely to be cost-effective in high-income countries for high-risk populations. Evidence is also required on the cost-effectiveness of different strategies in low to middle income countries and countries with high TB burden.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10